2019-07-16 Source
The 2019 National Pharmacy Week and Chinese Pharmaceutical Innovation and Development Conference was held in Shandong Building, Jinan, Shandong Province from July 15 to 17. The theme of this conference was “Value Reconstruction - Seeking Growth, Expanding Borders and Exploring the Future”. Policy escorting means that continue to boost domestic pharmaceutical industrial, commercial and retail enterprises with high-quality to stand out, seize the high-end of the industrial value chain, and further promote the integration of industry merger and acquisition integration. Innovation guiding refers to lead the high-quality development of medicine with reform and innovation, lead the iteration of drugstores with technological innovation, break the border to achieve great synergy, and seek new growth points, which cannot realize without the full use of technical means. Connection of markets indicates to create an ecological network, strive to broaden the internal and external boundaries of the enterprise, maximize the coordination of various resources to meet customer needs in-depth. Capital integration shows the pharmaceutical industry value reconstruction, which means the industry’s original capital pattern has been reshaped, the original valuation model has been changed, and the traditional value concept has been updated. The three-dimensional interpretation of the four dimensions will present the profound perspective of industry value reconstruction for the participants, who will work together to seek the growth point of industry value, broaden the boundary of industry value, and explore the future development of the industry.
At this conference, Minei Research Institute organized the Expert Committee of China’s Top 100 Pharmaceutical Industry Ranking List. Relying on the database of three terminals and six market terminals exclusively developed and operated by Menet for many years in China, and taking pharmaceutical enterprises as an object, the conference, from the two most important dimensions (innovation driving force and professional promotion force), appraised and selected “the Series Lists of 2018 Top 100 Pharmaceutical Industry of China”.
“The Series Lists of 2018 Top 100 Pharmaceutical Industry of China” can be divided into five sub-lists of “List of Top 100 Chinese Chemical Enterprises”, “List of Top 100 Chinese Medicinal Enterprises”, “List of Top 20 Chinese CRO (including CDMO) Enterprises”, “List of Top 20 Chinese Medical Device (including IVD) Enterprises”, “List of Top 20 Chinese Biomedical (including blood products, vaccines, insulin, etc.) Enterprises”.
With solid R & D and production strength and stable market promotion ability, Beijing Handian Pharmaceutical Co., Ltd. was successfully selected into “List of Top 100 Chinese Medicinal Enterprises”, the sub list of “The Series Lists of 2018 Top 100 Pharmaceutical Industry of China” and ranked 77th.
This selection focuses on the innovation driving force and professional promotion force of pharmaceutical enterprises. The innovation driving force is mainly judged by the R & D comprehensive index of the R & D investment of enterprises. The professional promotion force is rigidly defined according to the terminal quantitative data determined by the final selection needs of clinicians and patients, and finally quantitatively analyzed in combination with the data of three exclusive terminals and six market terminals of the intranet.
The total score of the selected enterprises consists of two parts: one is the innovation driving force of the enterprise, i.e. the R & D comprehensive index score of R & D investment in 2018, accounting for 40% of the total score; the other is the professional promotion force of the enterprise, namely the quantitative terminal data determined by the final selection needs of clinicians and patients in 2018, which is determined by combining the exclusive three terminals and six market terminal data of the intranet The score of quantitative analysis accounts for 60% of the total; “the Series Lists of 2018 Top 100 Pharmaceutical Industry of China” was highly concerned and actively participated by professional research institutions, industrial experts and scholars, entrepreneurs and industrial colleagues in the selection process, and was highly appraised. This selection event has a huge impact.
On the evening of July 15, in Jinan, Shandong Province, Minei Research Institute held the awarding ceremony of “the Series Lists of 2018 Top 100 Pharmaceutical Industry of China”. Menet, cooperated with Medicine Economic News solemnly had released 5 sub-lists and 260 selected enterprises, demonstrating the professional strength and influence of the top 100 enterprises of the Chinese pharmaceutical industry.
Prev: Han Dian Group Won Two Awards in “the Most Influential List of China’s Pharmaceutical Industry of 2018”
Next: the Establishment Conference of the Expert Committee of Grassroots Feasible Technology Co-organized By Beijing Han Dian Pharmaceutical Company Came to a Successful Conclusion